Back to Clinical Research

OHR “Mako” 1601

Status: Ongoing, but not recruiting participants Identifier: NCT02727881

OHR 1601: A Phase III study of Efficacy and Safety of Squalamine Lactate Opthalmic Solution, 0.2% twice daily in subjects with Neovascular AMD.

Condition: Age-Related Macular Degeneration

Study Type: Interventional

Duration: 36 weeks


  • Ages: 50 years to 110 years
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information on this study, please click here

Back to Clinical Research